Epigenomics AG: strategic in vitro diagnostics partnership with Abbott Molecular
Abbott obtains non-exclusive worldwide rights to Epigenomics' proprietary DNA methylation biomarker Septin 9
Anticipate European market launch in 2009; filing for U.S. approval in 2010
Epigenomics to receive an up-front fee, milestone payments and royalties
Option to expand partnership on multiple Epigenomics biomarkers to other cancer indications
Epigenomics AG has signed a non-exclusive strategic collaboration and license agreement in molecular diagnostics with Abbott, a global healthcare company. Under the agreement, Abbott and Epigenomics intend to develop an in vitro diagnostic blood test for the early detection of colorectal cancer based on Epigenomics' proprietary DNA methylation biomarker Septin 9.
The companies anticipate launching a CE-marked test in Europe in 2009 followed by regulatory filing for U.S. approval in 2010. Under the terms of the agreement, Epigenomics will receive an up-front fee, milestone payments and royalties on product sales.
The agreement also contains provisions for the evaluation by Abbott of some of Epigenomics' other proprietary biomarkers for additional cancer indications.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.